Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR-301 in Severe Traumatic Brain Injury
NCT06253923Phase 2Active, not recruiting
- Sponsor
- SHINKEI Therapeutics
- Start
- Jun 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in traumatic brain injury (TBI) comparing MR-301 with Placebo (2 arms). Primary endpoint: Frequency, severity, and type of adverse events and serious adverse events. Started Jun 2024; status: active, not recruiting.
02
Drugs
amantadine hydrochloride intravenous solution
03
Conditions
traumatic brain injury (TBI)
Beyond the preview
Go deeper on NCT06253923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06253923.